Annual Total Liabilities:
$6.12B+$973.80M(+18.91%)Summary
- As of April 2, 2025, VRTX annual total liabilities is $6.12 billion, with the most recent change of +$973.80 million (+18.91%) on December 31, 2024.
- During the last 3 years, VRTX annual total liabilities has risen by +$2.79 billion (+83.75%).
- VRTX annual total liabilities is now at all-time high.
Performance
VRTX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities:
$6.12B-$485.70M(-7.35%)Summary
- As of April 2, 2025, VRTX quarterly total liabilities is $6.12 billion, with the most recent change of -$485.70 million (-7.35%) on December 31, 2024.
- Over the past year, VRTX quarterly total liabilities has stayed the same.
- VRTX quarterly total liabilities is now -7.35% below its all-time high of $6.61 billion, reached on September 30, 2024.
Performance
VRTX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
VRTX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.9% | 0.0% |
| 3 y3 years | +83.8% | +66.5% |
| 5 y5 years | +174.2% | +66.5% |
VRTX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +83.8% | -7.3% | +82.8% |
| 5 y | 5-year | at high | +174.2% | -7.3% | +151.8% |
| alltime | all time | at high | >+9999.0% | -7.3% | >+9999.0% |
Vertex Pharmaceuticals Incorporated Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $6.12B(+18.9%) | $6.12B(-7.3%) |
| Sep 2024 | - | $6.61B(+23.4%) |
| Jun 2024 | - | $5.36B(-0.2%) |
| Mar 2024 | - | $5.37B(+4.3%) |
| Dec 2023 | $5.15B(+21.5%) | $5.15B(-1.2%) |
| Sep 2023 | - | $5.21B(+6.9%) |
| Jun 2023 | - | $4.88B(+7.4%) |
| Mar 2023 | - | $4.54B(+7.2%) |
| Dec 2022 | $4.24B(+27.2%) | $4.24B(+15.3%) |
| Sep 2022 | - | $3.68B(+0.8%) |
| Jun 2022 | - | $3.65B(+8.9%) |
| Mar 2022 | - | $3.35B(+0.5%) |
| Dec 2021 | $3.33B(+8.7%) | $3.33B(+7.9%) |
| Sep 2021 | - | $3.09B(+2.1%) |
| Jun 2021 | - | $3.03B(-3.5%) |
| Mar 2021 | - | $3.13B(+2.3%) |
| Dec 2020 | $3.06B(+37.2%) | $3.06B(-3.3%) |
| Sep 2020 | - | $3.17B(+17.5%) |
| Jun 2020 | - | $2.70B(+10.9%) |
| Mar 2020 | - | $2.43B(+8.9%) |
| Dec 2019 | $2.23B(+23.3%) | $2.23B(-1.2%) |
| Sep 2019 | - | $2.26B(+15.2%) |
| Jun 2019 | - | $1.96B(+7.9%) |
| Mar 2019 | - | $1.82B(+0.5%) |
| Dec 2018 | $1.81B(+20.4%) | $1.81B(+7.4%) |
| Sep 2018 | - | $1.69B(+4.1%) |
| Jun 2018 | - | $1.62B(+6.5%) |
| Mar 2018 | - | $1.52B(+1.2%) |
| Dec 2017 | $1.50B(-3.5%) | $1.50B(+7.8%) |
| Sep 2017 | - | $1.40B(-1.6%) |
| Jun 2017 | - | $1.42B(+12.2%) |
| Mar 2017 | - | $1.26B(-18.9%) |
| Dec 2016 | $1.56B(+10.9%) | $1.56B(+11.2%) |
| Sep 2016 | - | $1.40B(+1.5%) |
| Jun 2016 | - | $1.38B(+0.6%) |
| Mar 2016 | - | $1.37B(-2.4%) |
| Dec 2015 | $1.40B(+13.4%) | $1.40B(+3.5%) |
| Sep 2015 | - | $1.36B(+2.4%) |
| Jun 2015 | - | $1.33B(+13.5%) |
| Mar 2015 | - | $1.17B(-5.7%) |
| Dec 2014 | $1.24B(+28.7%) | $1.24B(-0.9%) |
| Sep 2014 | - | $1.25B(+32.2%) |
| Jun 2014 | - | $945.55M(-2.1%) |
| Mar 2014 | - | $966.23M(+0.4%) |
| Dec 2013 | $962.64M(-38.4%) | $962.64M(-15.2%) |
| Sep 2013 | - | $1.14B(+5.7%) |
| Jun 2013 | - | $1.07B(-26.1%) |
| Mar 2013 | - | $1.45B(-7.0%) |
| Dec 2012 | $1.56B(+22.5%) | $1.56B(+7.5%) |
| Sep 2012 | - | $1.45B(+6.8%) |
| Jun 2012 | - | $1.36B(+9.8%) |
| Mar 2012 | - | $1.24B(-2.8%) |
| Dec 2011 | $1.28B(+4.4%) | $1.28B(-6.3%) |
| Sep 2011 | - | $1.36B(+3.6%) |
| Jun 2011 | - | $1.31B(+14.6%) |
| Mar 2011 | - | $1.15B(-6.1%) |
| Dec 2010 | $1.22B(+42.2%) | $1.22B(-1.4%) |
| Sep 2010 | - | $1.24B(+49.8%) |
| Jun 2010 | - | $827.07M(+6.1%) |
| Mar 2010 | - | $779.69M(-9.2%) |
| Dec 2009 | $859.14M(+15.8%) | $859.14M(-10.9%) |
| Sep 2009 | - | $964.75M(+35.7%) |
| Jun 2009 | - | $710.82M(-17.3%) |
| Mar 2009 | - | $859.03M(+15.8%) |
| Dec 2008 | $741.61M(+124.6%) | $741.61M(+3.3%) |
| Sep 2008 | - | $717.66M(-1.8%) |
| Jun 2008 | - | $730.88M(+24.9%) |
| Mar 2008 | - | $585.25M(+77.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $330.18M(-20.6%) | $330.18M(+2.2%) |
| Sep 2007 | - | $323.11M(-6.7%) |
| Jun 2007 | - | $346.49M(+3.8%) |
| Mar 2007 | - | $333.80M(-19.7%) |
| Dec 2006 | $415.64M(+34.2%) | $415.64M(+5.4%) |
| Sep 2006 | - | $394.34M(-12.5%) |
| Jun 2006 | - | $450.48M(+54.4%) |
| Mar 2006 | - | $291.75M(-5.8%) |
| Dec 2005 | $309.82M(-39.3%) | $309.82M(-25.7%) |
| Sep 2005 | - | $417.26M(-12.0%) |
| Jun 2005 | - | $473.94M(-3.8%) |
| Mar 2005 | - | $492.72M(-3.4%) |
| Dec 2004 | $510.01M(-4.1%) | $510.01M(+2.0%) |
| Sep 2004 | - | $500.04M(-2.7%) |
| Jun 2004 | - | $513.76M(+0.3%) |
| Mar 2004 | - | $512.09M(-3.7%) |
| Dec 2003 | $531.57M(+21.6%) | $531.57M(+3.9%) |
| Sep 2003 | - | $511.39M(+7.9%) |
| Jun 2003 | - | $473.94M(+7.7%) |
| Mar 2003 | - | $440.04M(+0.7%) |
| Dec 2002 | $437.14M(-2.8%) | $437.14M(+3.4%) |
| Sep 2002 | - | $422.86M(-0.2%) |
| Jun 2002 | - | $423.79M(-0.4%) |
| Mar 2002 | - | $425.40M(-5.4%) |
| Dec 2001 | $449.78M(+5.3%) | $449.78M(+0.8%) |
| Sep 2001 | - | $446.08M(+15.7%) |
| Jun 2001 | - | $385.49M(+1.8%) |
| Mar 2001 | - | $378.84M(-11.3%) |
| Dec 2000 | $427.13M(+1740.2%) | $427.13M(-22.1%) |
| Sep 2000 | - | $547.96M(+169.7%) |
| Jun 2000 | - | $203.21M(+4.1%) |
| Mar 2000 | - | $195.19M(+741.0%) |
| Dec 1999 | $23.21M(+15.5%) | $23.21M(+26.8%) |
| Sep 1999 | - | $18.30M(-8.5%) |
| Jun 1999 | - | $20.00M(-1.0%) |
| Mar 1999 | - | $20.20M(+0.5%) |
| Dec 1998 | $20.10M(+2.6%) | $20.10M(+6.9%) |
| Sep 1998 | - | $18.80M(+20.5%) |
| Jun 1998 | - | $15.60M(+4.7%) |
| Mar 1998 | - | $14.90M(-24.0%) |
| Dec 1997 | $19.60M(+54.3%) | $19.60M(+14.0%) |
| Sep 1997 | - | $17.20M(+17.0%) |
| Jun 1997 | - | $14.70M(+2.1%) |
| Mar 1997 | - | $14.40M(+13.4%) |
| Dec 1996 | $12.70M(-7.3%) | $12.70M(+29.6%) |
| Sep 1996 | - | $9.80M(-18.3%) |
| Jun 1996 | - | $12.00M(+0.8%) |
| Mar 1996 | - | $11.90M(-13.1%) |
| Dec 1995 | $13.70M(+28.0%) | $13.70M(+7.9%) |
| Sep 1995 | - | $12.70M(-7.3%) |
| Jun 1995 | - | $13.70M(+25.7%) |
| Mar 1995 | - | $10.90M(+1.9%) |
| Dec 1994 | $10.70M(-7.0%) | $10.70M(-10.8%) |
| Sep 1994 | - | $12.00M(+6.2%) |
| Jun 1994 | - | $11.30M(+20.2%) |
| Mar 1994 | - | $9.40M(-18.3%) |
| Dec 1993 | $11.50M(+62.0%) | $11.50M(+12.7%) |
| Sep 1993 | - | $10.20M(+21.4%) |
| Jun 1993 | - | $8.40M(+3.7%) |
| Mar 1993 | - | $8.10M(+14.1%) |
| Dec 1992 | $7.10M(+44.9%) | $7.10M(+10.9%) |
| Sep 1992 | - | $6.40M(+8.5%) |
| Jun 1992 | - | $5.90M(+20.4%) |
| Mar 1992 | - | $4.90M(0.0%) |
| Dec 1991 | $4.90M(+22.5%) | $4.90M(+6.5%) |
| Sep 1991 | - | $4.60M(-2.1%) |
| Jun 1991 | - | $4.70M(+17.5%) |
| Dec 1990 | $4.00M | $4.00M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total liabilities?
- What is the all time high annual total liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual total liabilities year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total liabilities?
- What is the all time high quarterly total liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total liabilities?
The current annual total liabilities of VRTX is $6.12B
What is the all time high annual total liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total liabilities is $6.12B
What is Vertex Pharmaceuticals Incorporated annual total liabilities year-on-year change?
Over the past year, VRTX annual total liabilities has changed by +$973.80M (+18.91%)
What is Vertex Pharmaceuticals Incorporated quarterly total liabilities?
The current quarterly total liabilities of VRTX is $6.12B
What is the all time high quarterly total liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total liabilities is $6.61B
What is Vertex Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?
Over the past year, VRTX quarterly total liabilities has changed by $0.00 (0.00%)